On April 26, 2026, the inauguration ceremony of the Qingdao University Advanced Institute for Clinical Medicine (Yantai) and a strategic cooperation signing ceremony were held at the Affiliated Yantai Yuhuangding Hospital of Qingdao University. Wei Zhiqiang, President of Qingdao University, and Song Xicheng, Party Secretary and Dean of the Affiliated Yantai Yuhuangding Hospital of Qingdao University, attended the ceremony, delivered speeches, and unveiled the institute.

Shenzhen Cell Valley Biopharmaceutical Co., Ltd., a key player in the biopharma and cell therapy sectors, was invited to the event. Xiang Hua, Co-founder and Deputy General Manager of the company, officially signed a strategic cooperation agreement with the hospital, marking a new phase in deep industry-academia integration, clinical technology innovation, and result translation.

Witnessed by the guests, Shenzhen Cell Valley and the Affiliated Yantai Yuhuangding Hospital of Qingdao University formally completed the strategic partnership signing. Both parties agreed to take this agreement as a new starting point, fully leveraging their complementary strengths in clinical resources, technology R&D, research platforms, industrial operations, and talent development. They will pursue comprehensive, in-depth, and long-term stable collaboration in areas including innovative therapeutic technology R&D, efficient translation of research outcomes, joint laboratory construction, co-training of high-level medical and industrial professionals, precision medicine system development, and enhancement of regional healthcare services.

As a top-tier tertiary hospital in the region, the Affiliated Yantai Yuhuangding Hospital of Qingdao University possesses robust clinical resources, research capabilities, and a strong talent pool, and has long been committed to advancing clinical medical research and the application of high-end medical technologies. Shenzhen Cell Valley, an innovative enterprise focused on the cell and gene therapy (CGT) sector, consistently adheres to a clinical-need-driven approach, concentrating on cutting-edge technology R&D, platform development, and industrial implementation, continually providing safer, more effective, and more accessible innovative solutions for the treatment of cancer and major diseases.

This strategic partnership marks a milestone for healthcare and biopharma development in the Jiaodong region. The participating parties engaged in extensive discussions on core topics including clinical medical technology innovation, translation of frontier biotechnologies, industry collaboration for coordinated development, and the construction of a regional health ecosystem, building consensus and jointly charting a roadmap for cooperation.

 Looking ahead, Shenzhen Cell Valley will continue to uphold its original commitment to innovation, deepen industry-academia-research collaboration, and expand synergistic development with top-tier medical institutions and research organizations—driving industrial upgrading through technological breakthroughs and shaping a healthy future through open cooperation—as it steadily advances the development of China's biopharma and cell therapy industries.

Profile of Yantai Yuhuangding Hospital

Yantai Yuhuangding Hospital is a grade-A tertiary general hospital and a regional medical center in Shandong Province, ranking among the top prefectural and municipal hospitals in China in terms of comprehensive strength. As a nationally accredited stem cell clinical research filing base, the hospital has been deeply engaged in the frontier field of cell therapy, establishing an international-standard clinical research and translation platform and assembling a multidisciplinary team of specialists, with outstanding capabilities in both scientific research and clinical translation. In the National Health Commission's uation of stem cell clinical research projects, the hospital's two filed projects both received a Grade B rating—the highest in the province. Among them, the world's first project using human umbilical cord mesenchymal stem cell injection for the treatment of moderate-to-severe persistent allergic rhinitis has already been translated and implemented in Beidaihe.